Quadralynx develops voice dosimeters specifically designed to enhance speech clarity and volume for individuals with Parkinson’s and Alzheimer’s diseases. By providing real-time feedback on vocal performance, the technology addresses communication challenges that often lead to social isolation and decreased quality of life for these patients.
Funding
Funding not disclosed
Founders
Product
Problem
Individuals with Parkinson's and Alzheimer's diseases often experience diminished speech clarity and volume, leading to communication difficulties. These challenges can result in social isolation and a decreased quality of life.
Solution
Quadralynx provides voice dosimeters designed to improve speech for individuals with neurological disorders. The technology offers real-time feedback on vocal performance, helping users to modulate and enhance their speech. By addressing communication challenges, Quadralynx aims to improve the quality of life and reduce social isolation for individuals affected by Parkinson's and Alzheimer's diseases. The device provides immediate support for patients to improve their communication abilities.
Target Audience
The primary users are individuals with Parkinson's and Alzheimer's diseases who experience speech and communication difficulties.
Features
- Real-time vocal performance feedback
- Voice volume monitoring
- Designed for individuals with Parkinson's and Alzheimer's diseases